Cable Hill Partners’s Inovio Pharmaceuticals INO Stock Holding History

Cable Hill Partners’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$22K	–	402
2019 Q1	$22K	Buy	500 +83	+20%	+$4.18K	0.01%	359
2018 Q4	$20K	Hold	417	–	–	0.01%	349
2018 Q3	$28K	Buy	417 +334	+402%	+$18.6K	0.01%	262
2018 Q2	$4K	Hold	83	–	–	﹤0.01%	721
2018 Q1	$5K	Hold	83	–	–	﹤0.01%	659
2017 Q4	$5K	Sell	83 -21	-20%	-$1.3K	﹤0.01%	732
2017 Q3	$8K	Sell	104 -42	-29%	-$3.13K	﹤0.01%	642
2017 Q2	$14K	Buy	146 +83	+132%	+$7.1K	0.01%	335
2017 Q1	$5K	Hold	63	–	–	﹤0.01%	542
2016 Q4	$5K	Hold	63	–	–	﹤0.01%	550
2016 Q3	$7K	Hold	63	–	–	0.01%	498
2016 Q2	$8K	Hold	63	–	–	0.01%	411
2016 Q1	$7K	Hold	63	–	–	0.01%	418
2015 Q4	$6K	Hold	63	–	–	﹤0.01%	439
2015 Q3	$5K	Hold	63	–	–	﹤0.01%	499
2015 Q2	$7K	Hold	63	–	–	0.01%	522
2015 Q1	$6K	Hold	63	–	–	﹤0.01%	531
2014 Q4	$7K	Buy	+63	New	+$7.7K	0.01%	495

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cable Hill Partners's INO Position: Q2 2019 in Review

Cable Hill Partners sold out of Inovio Pharmaceuticals (INO) in Q2 2019, closing a stake of 500 shares — an estimated $22K sold.

Cable Hill Partners first reported a position in INO in Q4 2014 and held it in 18 quarters. The position peaked at $28K in Q3 2018. 126 funds tracked by Wall St. Rank hold INO as of Q2 2019.

Cable Hill Partners reported no remaining Inovio Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 500 Inovio Pharmaceuticals shares in Q2 2019, an estimated $22K.
Cable Hill Partners first reported a position in Inovio Pharmaceuticals in Q4 2014 and held it in 18 quarters.
Cable Hill Partners's Inovio Pharmaceuticals position peaked at $28K in Q3 2018.
126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.